Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albrecht Stoehr

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2013
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosisMaribel Rodriguez-Torres, Albrecht Stoehr, Edward J Gane, et al.
Zeitschrift Fur Gastroenterologie|September 18, 2020
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)Johannes Vermehren, Yvonne Serfert, Markus Cornberg, et al.
Zeitschrift Fur Gastroenterologie|July 16, 2024
ReLink strategy in diagnosed-but-untreated hepatitis C-positive patients in Germany: report from a single centerSarah Lange, Christina Baehr, Nur Irem Cakman-Hinrichs, et al.
British Journal of Haematology|May 15, 2004
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's diseaseChristian Hoffmann, Kai Uwe Chow, Eva Wolf, et al.
AIDS (London, England)|September 22, 2006
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionGuenther Schmutz, Mark Nelson, Thomas Lutz, et al.
Plos One|June 10, 2015
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical TrialBenjamin Heidrich, Hans-Jörg Cordes, Hartwig Klinker, et al.
Cancer|September 30, 2021
Outcomes of men with HIV and germ cell cancer: Results from an international collaborative studyMarcus Ulrich Hentrich, Mark Bower, Gedske Daugaard, et al.
AIDS Research and Therapy|August 17, 2021
Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohortTrevor A Crowell, Haoyu Qian, Carsten Tiemann, et al.
Haematologica|February 14, 2018
Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort studyPhilipp Schommers, Daniel Gillor, Marcus Hentrich, et al.
Open Forum Infectious Diseases|September 23, 2020
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS StudyChristoph D Spinner, Tim Kümmerle, Jochen Schneider, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2013
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosisMaribel Rodriguez-Torres, Albrecht Stoehr, Edward J Gane, et al.
Zeitschrift Fur Gastroenterologie|September 18, 2020
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)Johannes Vermehren, Yvonne Serfert, Markus Cornberg, et al.
Zeitschrift Fur Gastroenterologie|July 16, 2024
ReLink strategy in diagnosed-but-untreated hepatitis C-positive patients in Germany: report from a single centerSarah Lange, Christina Baehr, Nur Irem Cakman-Hinrichs, et al.
British Journal of Haematology|May 15, 2004
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's diseaseChristian Hoffmann, Kai Uwe Chow, Eva Wolf, et al.
AIDS (London, England)|September 22, 2006
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionGuenther Schmutz, Mark Nelson, Thomas Lutz, et al.
Plos One|June 10, 2015
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical TrialBenjamin Heidrich, Hans-Jörg Cordes, Hartwig Klinker, et al.
Cancer|September 30, 2021
Outcomes of men with HIV and germ cell cancer: Results from an international collaborative studyMarcus Ulrich Hentrich, Mark Bower, Gedske Daugaard, et al.
AIDS Research and Therapy|August 17, 2021
Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohortTrevor A Crowell, Haoyu Qian, Carsten Tiemann, et al.
Haematologica|February 14, 2018
Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort studyPhilipp Schommers, Daniel Gillor, Marcus Hentrich, et al.
Open Forum Infectious Diseases|September 23, 2020
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS StudyChristoph D Spinner, Tim Kümmerle, Jochen Schneider, et al.
Pageof 6